Evidence map›Paper›PMID 42531576›Full record

ArticleDiabetes & vascular disease research

Relationship between non-O blood groups and microvascular risk in type 2 diabetes.

Fabian O Lurquin, Elise L Petit, Philippe Oriot, Sylvie A Ahn, Michel P Hermans

Abstract readMulticenter Study
In one paragraph

Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fabian O LurquinDepartment of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.ORCID 0009-0005-9746-4489
Elise L PetitInstitute for Interdisciplinary Innovation in Healthcare (I3H), Université Libre de Bruxelles, Brussels, Belgium.
Philippe OriotCentre Hospitalier de Mouscron, Service d'Endocrinologie-Diabétologie, Mouscron, Belgium.
Sylvie A AhnPôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.
Michel P HermansDepartment of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionABO groups impact macroangiopathy risk in T2D. It is unknown whether such modulation extends to microvascular complications.MethodSingle-centre cross-sectional study including 1,006 T2D patients.ResultsPrevalence of overall microangiopathy was 51%. No significant differences (ANOVA) were observed between ABO groups in terms of age, sex, diabetes duration, BMI, hypertension, chronic kidney disease or diabetic foot. Insulin sensitivity and the hyperbolic HOMA product [BxS] were lower among non-O groups (-20% and -14%, respectively; p 0.001 and 0.013), while HbA1c and lifetime hyperglycaemia exposure were higher (+5% and +25%, respectively; p 0.006 and 0.002). Overall microangiopathy was more prevalent among non-O patients (+23%; p 0.001), as was neuropathy (+44%; p 0.005). Differences across ABO groups were significant for overall microangiopathy (p 0.009) and neuropathy (p 0.027) (ANOVA). In multivariate analysis, group A (vs O) was associated with overall microangiopathy (OR=1.62; 95%CI: 1.18-2.22; p 0.003) after adjustment for diabetes duration, HbA1c, smoking, remnant-C and hypertension.ConclusionT2D patients of blood group A have increased frequency of overall microangiopathy, regardless of other risk factors. Group O subjects exhibit better glucose homeostasis, with better insulin sensitivity and β-cell function. The ABO system therefore impacts both glucose homeostasis and microvascular susceptibility in T2D.

Indexed as

ABO Blood-Group SystemDiabetes Mellitus, Type 2Diabetic AngiopathiesAgedBiomarkersBlood GlucoseCross-Sectional StudiesDiabetic NeuropathiesFemaleFranceGlycated HemoglobinHumansInsulin ResistanceMaleMicrocirculationMiddle AgedABO Blood-Group SystemBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanABO blood groupsHOMAmicroangiopathytype 2 diabetesβ-cell function

Identifiers

PMID42531576
PMCPMC13424523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.